FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039496823> ?p ?o ?g. }

• W2039496823 endingPage "1596" @default.
• W2039496823 startingPage "1589" @default.
• W2039496823 abstract "Abstract The Spanish Myeloma Group conducted a trial to compare bortezomib/thalidomide/dexamethasone (VTD) versus thalidomide/dexamethasone (TD) versus vincristine, BCNU, melphalan, cyclophosphamide, prednisone/vincristine, BCNU, doxorubicin, dexamethasone/bortezomib (VBMCP/VBAD/B) in patients aged 65 years or younger with multiple myeloma. The primary endpoint was complete response (CR) rate postinduction and post–autologous stem cell transplantation (ASCT). Three hundred eighty-six patients were allocated to VTD (130), TD (127), or VBMCP/VBAD/B (129). The CR rate was significantly higher with VTD than with TD (35% vs 14%, P = .001) or with VBMCP/VBAD/B (35% vs 21%, P = .01). The median progression-free survival (PFS) was significantly longer with VTD (56.2 vs 28.2 vs 35.5 months, P = .01). In an intention-to-treat analysis, the post-ASCT CR rate was higher with VTD than with TD (46% vs 24%, P = .004) or with VBMCP/VBAD/B (46% vs 38%, P = .1). Patients with high-risk cytogenetics had a shorter PFS and overall survival in the overall series and in all treatment groups. In conclusion, VTD resulted in a higher pre- and posttransplantation CR rate and in a significantly longer PFS although it was not able to overcome the poor prognosis of high-risk cytogenetics. Our results support the use of VTD as a highly effective induction regimen prior to ASCT. The study was registered with http://www.clinicaltrials.gov (NCT00461747) and Eudra CT (no. 2005-001110-41)." @default.
• W2039496823 created "2016-06-24" @default.
• W2039496823 creator A5010881749 @default.
• W2039496823 creator A5013875524 @default.
• W2039496823 creator A5015898454 @default.
• W2039496823 creator A5016479494 @default.
• W2039496823 creator A5018662284 @default.
• W2039496823 creator A5020420490 @default.
• W2039496823 creator A5020952870 @default.
• W2039496823 creator A5020989412 @default.
• W2039496823 creator A5028498042 @default.
• W2039496823 creator A5031837957 @default.
• W2039496823 creator A5033034382 @default.
• W2039496823 creator A5034430204 @default.
• W2039496823 creator A5035515070 @default.
• W2039496823 creator A5047866471 @default.
• W2039496823 creator A5054952877 @default.
• W2039496823 creator A5060453493 @default.
• W2039496823 creator A5064147442 @default.
• W2039496823 creator A5073739479 @default.
• W2039496823 creator A5080697191 @default.
• W2039496823 creator A5081168775 @default.
• W2039496823 creator A5082983493 @default.
• W2039496823 creator A5082994505 @default.
• W2039496823 creator A5088242526 @default.
• W2039496823 date "2012-08-23" @default.
• W2039496823 modified "2023-10-17" @default.
• W2039496823 title "Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study" @default.
• W2039496823 cites W1978377409 @default.
• W2039496823 cites W1983715506 @default.
• W2039496823 cites W1991660588 @default.
• W2039496823 cites W1992231323 @default.
• W2039496823 cites W2015880063 @default.
• W2039496823 cites W2017303578 @default.
• W2039496823 cites W2025253157 @default.
• W2039496823 cites W2033024649 @default.
• W2039496823 cites W2036200625 @default.
• W2039496823 cites W2042761416 @default.
• W2039496823 cites W2044436186 @default.
• W2039496823 cites W2051146376 @default.
• W2039496823 cites W2055338149 @default.
• W2039496823 cites W2059733579 @default.
• W2039496823 cites W2063697325 @default.
• W2039496823 cites W2071434932 @default.
• W2039496823 cites W2075032656 @default.
• W2039496823 cites W2086692682 @default.
• W2039496823 cites W2089107230 @default.
• W2039496823 cites W2098422029 @default.
• W2039496823 cites W2114396320 @default.
• W2039496823 cites W2117237065 @default.
• W2039496823 cites W2126351771 @default.
• W2039496823 cites W2128515279 @default.
• W2039496823 cites W2146607984 @default.
• W2039496823 cites W2148188974 @default.
• W2039496823 cites W2148672632 @default.
• W2039496823 cites W2150254829 @default.
• W2039496823 cites W2151595053 @default.
• W2039496823 cites W2151989390 @default.
• W2039496823 cites W2153596485 @default.
• W2039496823 cites W2169183166 @default.
• W2039496823 cites W2321655863 @default.
• W2039496823 cites W2322962980 @default.
• W2039496823 cites W4293241248 @default.
• W2039496823 cites W4298434897 @default.
• W2039496823 doi "https://doi.org/10.1182/blood-2012-02-408922" @default.
• W2039496823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22791289" @default.
• W2039496823 hasPublicationYear "2012" @default.
• W2039496823 type Work @default.
• W2039496823 sameAs 2039496823 @default.
• W2039496823 citedByCount "415" @default.
• W2039496823 countsByYear W20394968232012 @default.
• W2039496823 countsByYear W20394968232013 @default.
• W2039496823 countsByYear W20394968232014 @default.
• W2039496823 countsByYear W20394968232015 @default.
• W2039496823 countsByYear W20394968232016 @default.
• W2039496823 countsByYear W20394968232017 @default.
• W2039496823 countsByYear W20394968232018 @default.
• W2039496823 countsByYear W20394968232019 @default.
• W2039496823 countsByYear W20394968232020 @default.
• W2039496823 countsByYear W20394968232021 @default.
• W2039496823 countsByYear W20394968232022 @default.
• W2039496823 countsByYear W20394968232023 @default.
• W2039496823 crossrefType "journal-article" @default.
• W2039496823 hasAuthorship W2039496823A5010881749 @default.
• W2039496823 hasAuthorship W2039496823A5013875524 @default.
• W2039496823 hasAuthorship W2039496823A5015898454 @default.
• W2039496823 hasAuthorship W2039496823A5016479494 @default.
• W2039496823 hasAuthorship W2039496823A5018662284 @default.
• W2039496823 hasAuthorship W2039496823A5020420490 @default.
• W2039496823 hasAuthorship W2039496823A5020952870 @default.
• W2039496823 hasAuthorship W2039496823A5020989412 @default.
• W2039496823 hasAuthorship W2039496823A5028498042 @default.
• W2039496823 hasAuthorship W2039496823A5031837957 @default.
• W2039496823 hasAuthorship W2039496823A5033034382 @default.
• W2039496823 hasAuthorship W2039496823A5034430204 @default.
• W2039496823 hasAuthorship W2039496823A5035515070 @default.
• W2039496823 hasAuthorship W2039496823A5047866471 @default.
• W2039496823 hasAuthorship W2039496823A5054952877 @default.

• next